The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs)
BackgroundThe use of CGP in guiding treatment decisions in aNSCLC with acquired resistance to ALK TKIs is questionable.MethodsWe prospectively assessed the impact of CGP on the decision-making process in ALK-rearranged aNSCLC patients following progression on 2nd/3rd-generation ALK TKIs. Physician’s...
Main Authors: | Ari Raphael, Amir Onn, Liran Holtzman, Julia Dudnik, Damien Urban, Waleed Kian, Aharon Y. Cohen, Mor Moskovitz, Alona Zer, Jair Bar, Natalie Maimon Rabinovich, Shirly Grynberg, Cecilie Oedegaard, Abed Agbarya, Nir Peled, Tzippy Shochat, Elizabeth Dudnik |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.874712/full |
Similar Items
-
TFG::ALK fusion in ALK positive large B-cell lymphoma: a case report and review of literature
by: Andrew Xiao, et al.
Published: (2023-05-01) -
Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
by: Giovanni Maria Iannantuono, et al.
Published: (2022-04-01) -
Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
by: Serena Stadler, et al.
Published: (2018-04-01) -
The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
by: Stephen P. Ducray, et al.
Published: (2019-07-01) -
BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors
by: Elizabeth Dudnik, et al.
Published: (2021-03-01)